Navigation Links
Depomed To Report Third Quarter Fiscal Year 2013 Financial Results On Tuesday, November 5, 2013
Date:10/25/2013

NEWARK, Calif., Oct. 25, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release third quarter fiscal year 2013 financial results after the market closes on Tuesday, November 5, 2013. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm Pacific time to discuss its results.

Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About Depomed
Depomed, Inc. is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and other products and product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.

CONTACT:
August J. Moretti  
Depomed, Inc.
650-462-5900

SOURCE Depomed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
2. Depomed To Present At Jefferies 2012 Global Health Care Conference
3. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
4. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
5. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
6. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
7. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
8. Depomed To Present At UBS Global Life Sciences Conference
9. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
10. Depomed Reports Third Quarter Financial Results
11. Depomed To Present At Lazard 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... TEL-AVIV , Israele, February 27, 2015 /PRNewswire/ ... continua nel suo sviluppo dell,innovativo sistema di monitoraggio ... il primo trial sull,uomo-   ... operante nello sviluppo di nuovo sistema per il ... congestizio (CHF), ha annunciato oggi di aver concluso ...
(Date:2/27/2015)... 27, 2015 An aggressive campaign to reduce ... rate of infection with a dangerous drug-resistant bacteria at ... Clostridium difficile, or C.diff, is a bacterium that can ... the colon. A recent article in the New England ... in the United States " asserts ...
(Date:2/27/2015)... 2015  In recognition of Rare Disease Day and ... bleeding disorders community, CSL Behring announced today ... of protein therapies to the World Federation of Hemophilia ... has worked to improve the lives of people with ... the WFH,s Global Alliance for Progress (GAP) Program aimed ...
Breaking Medicine Technology:Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3
... BARRX Medical Inc., a leader in the ... precancerous tissue from within the gastrointestinal tract, reported today ... (SAGES) has issued a new practice guideline for the ... reflux of stomach contents such as acid and bile ...
... , SAN FRANCISCO , June 1 ... to continue on FIRMAGON® (degarelix for injection) after one ... according to results of a Phase III extension study(1) ... PSA is commonly used in monitoring prostate cancer patients, ...
Cached Medicine Technology:The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Issues Practice Guideline Addressing the Management of Gastroesophageal Reflux Disease and Barrett's Esophagus 2The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Issues Practice Guideline Addressing the Management of Gastroesophageal Reflux Disease and Barrett's Esophagus 3The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Issues Practice Guideline Addressing the Management of Gastroesophageal Reflux Disease and Barrett's Esophagus 4Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 2Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 3Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 4Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 5
(Date:3/1/2015)... York, NY (PRWEB) March 01, 2015 ... and seek insurance rates for term or universal policies ... of some of the best life insurance companies for ... through the system at http://quotespros.com/life-insurance.html . , The ... the search portal are tied to a number of ...
(Date:3/1/2015)... York (PRWEB) March 01, 2015 ... lawsuit (( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go to ... must prepare a witness to provide testimony regarding ... the development of the Profemur device, Bernstein Liebhard ... U.S. District Court, Northern District of Iowa on ...
(Date:3/1/2015)... The number of transvaginal mesh lawsuits ( ... weeks in two New Jersey litigations where attorneys at ... announces. , A Case List updated on February ... proceeding established for products manufactured by Johnson & Johnson's ... when 90 fewer cases had been centralized. Additionally, 1,700 ...
(Date:3/1/2015)... ERISAPros is pleased to announce the ... professional staff of its Compliance Department. , Evelyn King, ... University-Mortiz College of Law. Prior to joining ERISAPros, Evelyn ... Fortune 500 companies as well as several privately held ... experiences range from benefit plan design, vendor management, administrative ...
(Date:3/1/2015)... California (PRWEB) March 01, 2015 Theme ... a new transition pack for Final Cut ... add accordion style transitions to any FCPX editors project.” ... given our users the tools needed to easily drag ... , The user gets many different controls over the ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2
... of a previously ischemic tissue is associated with ... in many organs including the liver. The injury ... consisting of an early stage started upon reoxygenation ... reactive oxygen species formation during reperfusion induces a ...
... and blood clots are often recommended to stop these ... polyps., However, interruption of these medications can place patients ... led by Shai Friedland at the VA Palo Alto ... polyps without interrupting anticoagulation. Their study will be published ...
... types of reconstruction of gastrointestinal continuity after gastric resection. ... how the geometry and flow conditions affect the gastroduodenal ... be the dominant cause of duodenal suture dehiscence, but ... remain unclear. , A research article to be ...
... MAResearchers at Brandeis, in collaboration with several other institutions ... economic costs of dengue fever, the endemic and epidemic ... problem in tropical and sub-tropical countries. The study, ... Journal of Tropical Hygiene , assessed the direct and ...
... Stressed about Work, Money and the EconomySeven out ... MeasuresWASHINGTON, May 7 Economic pressures are having ... 54, according to a new survey by the ... men are reporting significant stress related to work, ...
... The Board of Directors of Tyco International Ltd. (NYSE: ... 0.23 Swiss Francs (CHF) per share, payable on August 26, ... on July 31, 2009, subject to a required filing with ... share is the second installment of an annual dividend of ...
Cached Medicine News:Health News:A new light on the mechanisms of early stage liver reperfusion injury 2Health News:Dengue fever costs billions in health care, lost productivity and absenteeism 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 3
... System combines Invivo's AutoNet™ wireless networking ... and clinical information system (CIS) features. ... including alarms, full disclosure and vital ... patient to a bedside monitor or ...
The CIC Pro Clinical Information Center brings together vital patient information from multiple monitoring devices....
The Panorama Central Station includes bi-directional communication with Datascope bedside monitors, optional 72 hours of disclosure and a touch screen user interface....
... The Alaris System integrates drug ... practice guidelines,into a single, modular platform. ... or remove modules as you,need them, ... the bedside,to a minimum while managing ...
Medicine Products: